<DOC>
	<DOCNO>NCT01944969</DOCNO>
	<brief_summary>To evaluate long-term safety tolerability brexpiprazole adjunctive treatment patient Major Depressive Disorder ( MDD )</brief_summary>
	<brief_title>Long-term Safety Tolerability Study Brexpiprazole Adjunctive Treatment Patients With Major Depressive Disorder</brief_title>
	<detailed_description>This extension safety study terminate early one lead-in study ( 14571A ) elderly terminate Sponsor consider sufficient long-term safety data already collect development programme population age 18-65 yr .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Brexpiprazole</mesh_term>
	<criteria>The patient judge benefit adjunctive treatment brexpiprazole accord clinical opinion investigator . The patient MDD entry leadin brexpiprazole study , NCT01838681 / 14570A NCT01837797 / 14571A , diagnose accord DSMIVTRâ„¢ . The patient agree protocoldefined use effective contraception . The patient disease take medication could , investigator 's opinion , interfere assessment safety , tolerability , efficacy , interfere conduct interpretation study . The patient diagnose psychiatric disorder MDD leadin study NCT01838681 / 14570A NCT01837797 / 14571A . The patient , opinion investigator accord CSSRS , significant risk suicide . The patient relevant medical history current presence systemic disease . The patient , Baseline Visit abnormal ECG , investigator 's opinion , clinically significant . The patient moderate severe ongoing adverse event relate study medication leadin study consider potential safety risk investigator . The patient , investigator 's opinion , unlikely comply protocol unsuitable reason . Other inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>